Monascus Pilosus Fermented Composition for NAFLD Lipid Reduction

The patent uses Monascus pilosus fermented product as an intermediary substance that mediates between the gut microbiota and liver metabolism. The fermented product contains specific metabolites that act as signaling molecules to regulate lipid metabolism and reduce liver fat accumulation without direct toxic effects, thus resolving the contradiction between effectiveness and safety.

The invention leverages the body's own metabolic pathways and gut microbiota to achieve therapeutic effects. The Monascus pilosus fermented product works by modulating existing physiological processes rather than introducing aggressive external interventions, allowing the body to self-regulate liver fat metabolism through natural mechanisms, thereby ensuring both effectiveness and safety.

The patent extracts the essential beneficial components from Monascus pilosus fermentation process, isolating the key metabolites and active compounds responsible for gut microbiota modulation. By taking out only the necessary active ingredients rather than using whole probiotic cultures, the formulation complexity is reduced while maintaining the ability to improve gut ecological balance.

The invention changes the parameters of the fermented product formulation by controlling fermentation conditions, extraction methods, and concentration levels to optimize the profile of beneficial metabolites. By adjusting parameters such as pH, temperature, and fermentation time during production, the patent achieves stable gut microbiota modulation effects with a simplified final product formulation.